tldrdaily.news logo

Promising RNAi Treatment Lowers Blood Pressure in Groundbreaking Study

1 min read
Source: Endpoints News
Promising RNAi Treatment Lowers Blood Pressure in Groundbreaking Study
Photo: Endpoints News
TL;DR Summary

Alnylam Pharmaceuticals' RNA interference treatment, zilebesiran, demonstrated the ability to reduce blood pressure for six months in a mid-stage clinical trial. The company aims to develop zilebesiran as an add-on or alternative to daily blood pressure medications.

Topics:top-news#alnylam-pharmaceuticals#blood-pressure#clinical-trial#health#rna-interference-treatment#zilebesiran
Share this article
  1. Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study  Endpoints News
  2. Major Study Confirms Salt's Deadly Effect on Blood Pressure  U.S. News & World Report
  3. Reducing systolic blood pressure to less than 120 mm Hg reduced cardiovascular event risk  American Heart Association
  4. New Study Reveals Universal Blood Pressure Reduction Strategy, Effective Even With Medication  SciTechDaily
  5. RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1  TCTMD

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

0 min

vs 1 min read

Condensed

68%

115 → 37 words

Want the full story? Read the original article

Read on Endpoints News